Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at the American College of Gastroenterology (ACG) 2024 Annual Meeting in Philadelphia, Oct. 25-30, 2024.

Guardant and its research partners will share real-world data demonstrating poor patient compliance with repeat stool-based screening. A study of more than 350,000 patients shows that less than half of patients who underwent stool-based CRC screening completed the retesting recommended in clinical guidelines over the following four-year period, highlighting the need for alternative options to improve overall compliance to repeat testing.

A second presentation will report on the one-year outcomes of individuals tested with Guardant’s Shield™ blood test for CRC screening in the ECLIPSE study to understand the implications of “false positive” results. Study results demonstrate that the rate of non-colorectal malignancies does not differ in those who tested positive with Shield compared to those who tested negative.

“Research has clearly demonstrated the value of colorectal cancer screening in detecting cancer early, when it is most treatable, but screening is only effective if an individual completes the test,” said Craig Eagle, MD, chief medical officer at Guardant Health. “We look forward to sharing findings at the ACG meeting that support the potential of a blood-based screening option like the Shield test to improve overall screening rates among the millions of eligible individuals who may prefer a more pleasant screening option.”

Guardant Health and collaborator presentations at ACG 2024

The full abstracts for Guardant Health and a list of all abstracts being presented at the ACG Annual Meeting can be found on the ACG meeting website.

For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241028597268/en/